Massachusetts, USA-based Alnylam Pharmaceuticals (Nasdaq: ALNY) is presenting detailed data from its Phase III APOLLO study into patisiran at the European ATTR Amyloidosis Meeting in Paris.
The company’s share price, which was already riding high after topline results, revealed in September, showed the candidate had met its primary and secondary endpoints, is already up more than 15% on the news.
Patisiran is an experimental therapy that targets the hereditary form of ATTR amyloidosis, a rare and severe disease in which abnormal proteins accrete in the body.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze